Oncolytics Biotech Reschedules AGM for Audited Financials
Ticker: ONCY · Form: 6-K · Filed: Dec 10, 2025 · CIK: 1129928
Sentiment: neutral
Topics: agm, rescheduled, financials
TL;DR
Oncolytics Biotech AGM pushed to Dec 19th, 2025 due to audit delays. Watch financials.
AI Summary
Oncolytics Biotech Inc. has rescheduled its annual general meeting of shareholders to December 19, 2025. The meeting will now take place at 10:00 AM PST and will be held virtually. The company cited the need for additional time to finalize its audited financial statements for the fiscal year ended December 31, 2024, as the reason for the postponement.
Why It Matters
Shareholders need to be aware of the rescheduled meeting date to participate in important corporate decisions. The delay in financial statements may indicate potential issues or complexities in the company's financial reporting.
Risk Assessment
Risk Level: medium — Rescheduling an AGM due to delays in audited financial statements can sometimes signal underlying financial reporting issues or complexities that warrant closer investor scrutiny.
Key Players & Entities
- Oncolytics Biotech Inc. (company) — Registrant
- December 19, 2025 (date) — Rescheduled AGM date
- December 31, 2024 (date) — Fiscal year end for audited financials
FAQ
What is the new date and time for the rescheduled annual general meeting?
The annual general meeting has been rescheduled to December 19, 2025, at 10:00 AM PST.
Why was the annual general meeting rescheduled?
The meeting was rescheduled to allow the company additional time to finalize its audited financial statements for the fiscal year ended December 31, 2024.
How will the annual general meeting be conducted?
The meeting will be held virtually.
What is the fiscal year end for which the audited financial statements are being finalized?
The audited financial statements are for the fiscal year ended December 31, 2024.
What is the Commission File Number for Oncolytics Biotech Inc.?
The Commission File Number is 001-38512.
Filing Stats: 332 words · 1 min read · ~1 pages · Grade level 17 · Accepted 2025-12-09 18:02:43
Filing Documents
- form6krescheduledmeeting.htm (6-K) — 17KB
- rescheduledmeeting.htm (EX-99.1) — 20KB
- 0001129928-25-000095.txt ( ) — 38KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date December 9, 2025 Kirk Look Chief Financial Officer